危重症患者肾脏替代治疗效应的异质性:基于日本ICU登记库的多中心观察性研究
该多中心观察性研究纳入日本ICU登记库2018至2023年成人ICU患者,排除终末期肾病、早期死亡、再入院或肾功能正常者;暴露为ICU期间RRT,主要终点为住院死亡率。经1:1倾向评分匹配后分析18,794例(每组9,397例),RRT平均与住院死亡率升高相关(风险差6.1个百分点,95%CI 3.4-8.7)。基于机器学习的因果森林算法显示治疗效应存在显著异质性(rank-weighted平均治疗效应-8.2个百分点,95%CI -9.7至-6.7)。血清肌酐升高、尿量减少及血尿素氮升高者可能从RRT获得生存获益,而肾功能相对保留者更可能与受害相关。
要点
- 经倾向评分匹配后,RRT平均与住院死亡率升高相关(风险差6.1个百分点,95%CI 3.4-8.7),提示不应不加选择地启动RRT。
- 因果森林算法检出显著治疗效应异质性(rank-weighted平均治疗效应-8.2个百分点,95%CI -9.7至-6.7),支持按患者特征分层决策。
- 血清肌酐升高、尿量减少、血尿素氮升高的患者亚组可能从RRT获得死亡率获益,是床旁考虑启动RRT的候选人群。
- 肾功能相对保留的患者接受RRT更可能与受害相关,对此类患者应更审慎评估RRT指征。
- 该研究为观察性设计,结果支持数据驱动的RRT指征定义,但不能替代随机试验确立因果关系。
适用人群与场景
- 纳入:2018至2023年入住日本ICU的成人患者(日本Intensive Care Patient Database登记库)。
- 排除:终末期肾病患者、早期死亡者、再入院者、肾功能正常者。
- 场景:ICU住院期间;不涉及院前或急诊抢救室阶段。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:多中心观察性研究,数据来自日本全国ICU登记库(Japanese Intensive Care Patient Database),2018至2023年成人ICU患者,排除终末期肾病、早期死亡、再入院或肾功能正常者。
- 暴露为ICU期间RRT,主要终点为住院死亡率;经1:1倾向评分匹配后分析18,794例(每组9,397例)。
- 平均效应:RRT与住院死亡率升高相关,风险差6.1个百分点(95%CI 3.4-8.7)。
- 异质性:机器学习因果森林算法显示显著治疗效应异质性,rank-weighted平均治疗效应-8.2个百分点(95%CI -9.7至-6.7)。
- 亚组方向:血清肌酐升高、尿量减少、血尿素氮升高者可能从RRT获得死亡率获益;肾功能相对保留者更可能与受害相关。
证据类型、等级与局限
- 证据类型:多中心观察性研究(非随机、非干预),使用倾向评分匹配和机器学习因果森林方法估计异质性治疗效应。
- 局限:观察性设计存在残余混杂可能;原文未报告证据等级或推荐强度;原文未报告各亚组的具体效应量及95%CI。
对床旁实践的改变
- 支持对ICU患者启动RRT采取数据驱动的分层思路:肌酐升高、尿量减少、尿素氮升高者更可能获益,肾功能相对保留者应更审慎。
- 提醒RRT总体平均与死亡率升高相关(风险差6.1个百分点),不应将RRT视为对所有危重症患者普遍有益。
- 该结果为观察性研究,不能据此确立RRT与死亡率的因果关系,具体启动时机与指征仍需结合随机试验证据及个体评估。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: Randomized trials evaluating the timing of renal replacement therapy (RRT) have informed current practice toward more conservative initiation strategies because of the lack of mortality benefit from early initiation. However, the optimal indications for RRT to offer lifesaving benefits remain uncertain. We aimed to estimate heterogeneous treatment effect of RRT and to identify patient groups associated with benefit or harm.
DESIGN: Multicenter observational study.
SETTING: A nationwide intensive care registry in Japan, Japanese Intensive Care Patient Database.
PATIENTS: Adult patients who were admitted to the ICUs from 2018 through 2023 were included, excluding those with end-stage kidney disease, early death, readmission, or normal renal function.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Exposure was RRT during the ICU stay. Hospital mortality was the primary outcome. After 1:1 propensity score matching to adjust for confounding, 18,794 patients (9,397 per group) were analyzed. On average, RRT was associated with higher hospital mortality (risk difference, 6.1% points [95% CI, 3.4-8.7]). However, our machine learning-based causal forest algorithm showed substantial heterogeneity of treatment effects heterogeneity of treatment effects (HTEs) (rank-weighted average treatment effect, -8.2 percentage points [95% CI, -9.7 to -6.7]). Patients characterized by elevated serum creatinine, reduced urine output, and elevated blood urea nitrogen levels showed potential mortality benefit from RRT, whereas relatively preserved renal function was more likely to be associated with harm.
CONCLUSIONS: Although RRT was associated with an increased risk of hospital mortality overall, HTEs were identified in selected subgroups that may benefit from RRT. These findings support a data-driven approach to defining clinically applicable optimal RRT indications to guide more judicious use of RRT.
参考来源
- Nakamura S, Inoue K, Takahashi K, et al. Heterogeneous Treatment Effects of Renal Replacement Therapy in Critically Ill Patients: A Multicenter Observational Study Using a Japanese ICU Registry. Crit Care Med. 2026. PMID: 42573413. doi:10.1097/CCM.0000000000007282
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。